Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions

NCT02941731 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: HIP1403
DRUG: HGP0919

Sponsor

Hanmi Pharmaceutical Company Limited